The effect of bucolome on the canalicular bile formation and sulfobromophthalein transport maximum in the dog.

Abstract Bucolome (BC. 1-cyclohexyl-5- n -2,4,6-trioxoperhydropyrimidine), which was developed and used as a non-steroid, anti-inflammatory drug, has been reported to decrease the plasma bilirubin and sulfobromophthalein (BSP) levels in man and rats. Since this drug is also a choleretic. the effect of this drug on the BSP transport maximum (BSP Tm) and canalicular bile formation was studied in the dog. Intravenous administration of BC (10 mg/kg BW) increased the bile flow by 130 per cent in dogs without BSP infusion and 71 per cent in dogs with BSP infusion. Bile to plasma concentration ratio of [ 14 C]erythritol was decreased only 10 per cent by BC administration, and thus BC-induced choleresis was suggested to be primarily of canalicular origin. Neither BSP Tm nor bile salt excretion rate was significantly changed by BC' administration. These results indicate that the increased clearance of BSP from the plasma by this drug can not be attributed to the enhancement of hepatic transport process. Furthermore, the results are compatible with the currently proposed view that the dependency of BSP Tm on the bile salt induced choleresis is not due to the increased canalicular bile flow, but due to the increased excretion of bile salts into the bile.